Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.57 |
| ▸ | PLK1 | P53350 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.55 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | HRH1 | P35367 | 1/20 | 0.55 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL921527 | 0.90 | KCNH2 (0.59) | MEN1KMT2ACYP3A4CYP2C19CYP2D6 | |
| SCHEMBL924009 | 0.89 | KCNH2 (0.63) | MEN1KMT2ACYP3A4CYP2C19CYP2D6 | |
| SCHEMBL922935 | 0.89 | KMO (0.61) | MEN1KMT2AHTTCHRM1CHRM2 | |
| SCHEMBL923592 | 0.89 | KCNH2 (0.59) | MEN1KMT2ACYP3A4CYP2C19CYP2D6 | |
| SCHEMBL921108 | 0.88 | KCNH2 (0.63) | MEN1KMT2ACHRM1CHRM2CHRM4 | |
| SCHEMBL921359 | 0.87 | KCNH2 (0.62) | MEN1KMT2ACYP3A4CYP2C19CYP2D6 | |
| SCHEMBL921533 | 0.86 | CHRM1 (0.53) | MEN1KMT2ACYP3A4CYP2C19CYP2D6 | |
| SCHEMBL921491 | 0.86 | KCNH2 (0.61) | MEN1KMT2ACYP3A4CYP2C19CYP2D6 | |
| SCHEMBL923142 | 0.86 | CHRM1 (0.72) | KMT2AHTTCHRM1CHRM2CHRM4 | |
| SCHEMBL4226939 | 0.85 | CHRM1 (0.78) | MEN1KMT2ACYP3A4CYP2C19CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108577-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2012-05-03 | — | — | US | disclosed |
| EP-2289890-A1 | Compounds for the treatment of multi-drug resistant bacterial infections | AstraZeneca AB (SE) | 2011-03-02 | — | — | EP | disclosed |
| US-7875715-B2 | 6-[({1-[2-(7-methoxy-2-oxoquinoxalin-1(2H)-yl)ethyl]piperidin-4-yl}amino)methyl]-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one; antibacteria; methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant coagulase-negative staphylococci (MRCNS), penicillin-resistant Streptococcus pneumoniae | ASTRAZENECA AB (SE) | 2011-01-25 | — | — | US | disclosed |
| US-20100152441-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108577-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | PIGS, BPGM, IPMK | MEN1 2771/4885KMT2A 3561/4885CYP3A4 3414/4885 |
| US-20100152441-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | PIGS, BPGM, IPMK | MEN1 2771/4885KMT2A 3561/4885CYP3A4 3414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.